|Articles|October 30, 2017
The Emergence of the Few: M&A in the CRO Industry
Author(s)Craig Morgan
As the size, complexity, duration, cost, and globalization of clinical trials has grown, pharmaceutical and biotech companies have moved to outsource clinical activities to CROs to achieve a wide range of objectives.
Advertisement
Internal server error